FDA's new-drug approvals to reach at least 21 this year

12/21/2008 | Houston Chronicle (tiered subscription model)

The FDA is poised to clear at least 21 new medicines this year, increasing from 18 in 2007, despite the agency's failure to meet review deadlines for at least 15 treatments. Industry executives cited tougher approval standards as one reason for the delays. John Jenkins, director of the FDA's Office of New Drugs, said the agency evaluates "each application on its merits."

View Full Article in:

Houston Chronicle (tiered subscription model)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Chief, Product Review Branch
FDA/Center for Biologics Evaluation and Research
Silver Spring, MD
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ